Association between the Interleukin-1 Receptor Antagonist (IL1RN) Variable Number of Tandem Repeats (VNTR) Polymorphism and Lymphoma

Introduction: lymphoma is a common hematopoietic cancer. immunosuppression is one of the main risk factors for the development of lymphoma. the interleukin (il)-1 receptor antagonist il1rn, which binds to the il-1 receptor, moderates a variety of immune responses related to il-1. we aimed to assess the impact of il1rn variable number of tandem repeats (vntr) polymorphism on lymphoma risk in an iranian population sample. materials and methods: dna was extracted from peripheral blood of 120 subjects with non-hodgkin lymphoma (nhl), 50 subjects with hodgkin’s lymphoma (hl), and 186 unrelated healthy individuals. il1rn vntr polymorphism was detected using polymerase chain reaction. results: our findings revealed that the il1rn vntr polymorphism was associated with protection against nhl (p≤0.001, or: 0.30, 95% ci: 0.18-0.53). the il1rn 2 allele significantly decreased the risk of nhl (p = 0.023, or = 0.66, 95%ci = 0.46–0.93). in addition, we found that il1rn 1/2 was associated with a lower risk of hl (p ≤0.001, or = 0.24, 95%ci = 0.12–0.50). conclusion: our results suggest that the presence of il1rn vntr polymorphism is associated with a decreased risk of lymphoma in an iranian subpopulation in southeast iran.